

# Mentz Rj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3938371/publications.pdf>

Version: 2024-02-01

373  
papers

13,427  
citations

34105

52  
h-index

33894

99  
g-index

396  
all docs

396  
docs citations

396  
times ranked

13451  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertensive Diseases in Pregnancy and Kidney Function Later in Life. Mayo Clinic Proceedings, 2022, 97, 78-87.	3.0	2
2	Physical Rehabilitation in Older Patients Hospitalized with Acute Heart Failure and Diabetes: Insights from REHAB-HF. American Journal of Medicine, 2022, 135, 82-90.	1.5	8
3	Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. Journal of Cardiac Failure, 2022, 28, 334-338.	1.7	2
4	Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial. JAMA Cardiology, 2022, 7, 140.	6.1	5
5	Dysglycemia and incident heart failure among blacks: The jackson heart study. American Heart Journal, 2022, 245, 1-9.	2.7	3
6	Race Differences in Quality of Life following a Palliative Care Intervention in Patients with Advanced Heart Failure: Insights from the Palliative Care in Heart Failure Trial. Journal of Palliative Medicine, 2022, 25, 296-300.	1.1	3
7	Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemporary Clinical Trials, 2022, 113, 106646.	1.8	3
8	An evaluation of torsemide in patients with heart failure and renal disease. Expert Review of Cardiovascular Therapy, 2022, 20, 5-11.	1.5	6
9	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. American Heart Journal, 2022, 245, 110-116.	2.7	3
10	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008797.	3.9	7
11	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 916-923.	1.7	5
12	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. Journal of Cardiac Failure, 2022, 28, 1267-1277.	1.7	3
13	Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. JACC: Heart Failure, 2022, 10, 129-138.	4.1	9
14	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	2.8	21
15	Heart Month – A Historical Look and Simple “Walk” of Acknowledgement in the Present. Journal of Cardiac Failure, 2022, 28, 169-170.	1.7	1
16	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	30.7	341
17	Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women. Journal of the American Heart Association, 2022, 11, e022514.	3.7	9
18	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	1.7	23

#	ARTICLE	IF	CITATIONS
19	In-Hospital Outcomes in Pregnancy After Heart Transplantation. American Journal of Cardiology, 2022, 172, 68-72.	1.6	2
20	Inclusion and diversity in clinical trials: Actionable steps to drive lasting change. Contemporary Clinical Trials, 2022, 116, 106740.	1.8	39
21	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIO&OumlD&K</sc> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	7.1	23
22	Spirituality in Patients With Heart&Aacute;Failure. JACC: Heart Failure, 2022, 10, 217-226.	4.1	12
23	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
24	Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 1349-1354.	1.7	6
25	Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool. Journal of Cardiac Failure, 2022, 28, 1456-1463.	1.7	18
26	Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2022, 145, 1105-1107.	1.6	0
27	Sleep Breathing Disorders in Heart Failure. Cardiology Clinics, 2022, 40, 183-189.	2.2	2
28	Trends in HF Hospitalizations Among&Aacute;Young Adults in the United States From 2004 to 2018. JACC: Heart Failure, 2022, 10, 350-362.	4.1	21
29	International Collaborations in Heart Failure: JCF in Latin America. Journal of Cardiac Failure, 2022, 28, 695-696.	1.7	0
30	The need for increased pragmatism in cardiovascular clinical trials. Nature Reviews Cardiology, 2022, 19, 737-750.	13.7	22
31	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 146, 808-818.	1.6	33
32	Intervention Adherence in REHAB&Aacute;HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events. Journal of the American Heart Association, 2022, 11, .	3.7	5
33	Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Cardiovascular Diabetology, 2022, 21, .	6.8	3
34	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. Circulation, 2022, 146, 80-90.	1.6	32
35	Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. Trends in Cardiovascular Medicine, 2021, 31, 111-116.	4.9	4
36	Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2021, 27, 286-294.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. <i>Journal of Cardiac Failure</i> , 2021, 27, 607-609.	1.7	1
38	Differences between patients with cardiovascular disease and cancer referred for palliative care. <i>American Heart Journal</i> , 2021, 233, 5-9.	2.7	2
39	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021, 8, 662-669.	3.1	5
40	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	1.7	4
41	The Future of the <i>Journal of Cardiac Failure</i> : A Reinvigorated Focus on People, Partnerships and Presentation. <i>Journal of Cardiac Failure</i> , 2021, 27, 1.	1.7	3
42	Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 322-325.	1.6	4
43	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	2.6	4
44	Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF. <i>Journal of Cardiac Failure</i> , 2021, 27, 1476-1478.	1.7	1
45	Acute cardiovascular hospitalizations and illness severity before and during the COVID-19 pandemic. <i>Clinical Cardiology</i> , 2021, 44, 656-664.	1.8	6
46	Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. <i>American Heart Journal</i> , 2021, 233, 1-4.	2.7	1
47	Egg Consumption and Risk of Cardiovascular Disease: a Critical Review. <i>Current Emergency and Hospital Medicine Reports</i> , 2021, 9, 25-37.	1.5	3
48	Diversity, Equity and Inclusion at the <i>Journal of Cardiac Failure</i> . <i>Journal of Cardiac Failure</i> , 2021, 27, 263-264.	1.7	3
49	Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017320.	3.7	19
50	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	2.3	5
51	Thoughtful selection and use of scientific terms in clinical research: the case of "pragmatic" trials. <i>Journal of Investigative Medicine</i> , 2021, 69, 1056-1058.	1.6	6
52	Relationship of physical function with quality of life in older patients with acute heart failure. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1836-1845.	2.6	5
53	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	3.9	24
54	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. <i>Current Heart Failure Reports</i> , 2021, 18, 132-143.	3.3	1

#	ARTICLE	IF	CITATIONS
55	The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders. <i>Journal of Cardiac Failure</i> , 2021, 27, 386.	1.7	1
56	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	4.1	28
57	Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. <i>Journal of Medical Economics</i> , 2021, 24, 698-705.	2.1	6
58	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 145, 165-168.	1.6	8
59	Pragmatic Design of Randomized Clinical Trials for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 325-335.	4.1	22
60	Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2021, 27, 1175-1184.	1.7	3
61	Worsening Heart Failure Events in HFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 383-385.	4.1	1
62	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	3.9	30
63	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	4.1	23
64	Drugs of Abuse and Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1260-1275.	1.7	13
65	Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	2
66	The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 662-669.	1.7	8
67	Survival in Patients with Non-Ischemic Cardiomyopathy with Preserved versus Reduced Ejection Fraction. <i>CJC Open</i> , 2021, 3, 1333-1340.	1.5	2
68	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021, 143, 2370-2383.	1.6	56
69	Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1374-1381.	1.7	13
70	A Case for Re-Gifting. <i>JACC: Case Reports</i> , 2021, 3, 1010-1012.	0.6	0
71	Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. <i>New England Journal of Medicine</i> , 2021, 385, 203-216.	27.0	267
72	Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. <i>JACC: Heart Failure</i> , 2021, 9, 484-493.	4.1	10

#	ARTICLE	IF	CITATIONS
73	Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020920.	3.7	14
74	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	1.7	7
75	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 471-481.	4.1	38
76	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 826-836.	1.7	30
77	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	4.1	8
78	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). <i>American Journal of Cardiology</i> , 2021, 158, 59-65.	1.6	1
79	Participation in a Heart Failure Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008242.	3.9	12
80	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	3.7	10
81	Sleep quality, depressive symptoms, and transplant outcomes: Follow-up analyses from the ADAPT prospective pilot study. <i>General Hospital Psychiatry</i> , 2021, 72, 53-58.	2.4	3
82	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	1.6	1
83	Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. <i>Journal of Cardiac Failure</i> , 2021, 27, 942-948.	1.7	0
84	Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 876-886.	4.1	19
85	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	1.7	8
86	Physical Functioning in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 1002-1016.	1.7	2
87	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. <i>Journal of the American Heart Association</i> , 2021, 10, e021276.	3.7	6
88	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	2.7	3
89	Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 747-757.	4.1	32
90	OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2021, 67, 192-195.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation: Heart Failure</i> , 2021, , CIRCHEARTFAILURE121008403.	3.9	1
92	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCCEL trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.8	6
93	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012.	2.8	48
94	Following Our Hearts: Prioritizing Self-care and Wellness. <i>Journal of Cardiac Failure</i> , 2021, 27, 1163-1164.	1.7	1
95	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	4.1	41
96	JCF Year-In-Review 2021 and the Path Forward. <i>Journal of Cardiac Failure</i> , 2021, 27, 1307-1309.	1.7	2
97	Influence of donor brain death duration on outcomes following heart transplantation: A United Network for Organ Sharing Registry analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1345-1353.e2.	0.8	18
98	Increasing the United States heart transplant donor pool with donation after circulatory death. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, e307-e309.	0.8	53
99	Sleep Breathing Disorders in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 45-51.	2.1	32
100	Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. <i>American Heart Journal</i> , 2020, 219, 47-57.	2.7	45
101	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	8.6	4
102	Renal Outcomes in Patients Bridged to Heart Transplant With a Left Ventricular Assist Device. <i>Annals of Thoracic Surgery</i> , 2020, 110, 567-574.	1.3	5
103	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 754-758.	7.1	4
104	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	8.6	38
105	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020, 88, 105775.	1.8	5
106	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	8.6	63
107	Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. <i>American Heart Journal</i> , 2020, 230, 25-34.	2.7	6
108	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. <i>American Heart Journal</i> , 2020, 230, 35-43.	2.7	8

#	ARTICLE	IF	CITATIONS
109	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 435-450.	2.8	7
110	Biomarkers in Advanced Heart Failure. Circulation: Heart Failure, 2020, 13, e006840.	3.9	3
111	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. Journal of the American Heart Association, 2020, 9, e014990.	3.7	19
112	Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure. American Heart Journal, 2020, 229, 1-17.	2.7	85
113	In-hospital outcomes after bariatric surgery in patients with heart failure. American Heart Journal, 2020, 230, 59-62.	2.7	5
114	Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). American Journal of Cardiology, 2020, 136, 100-106.	1.6	3
115	Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials. Statistics in Medicine, 2020, 39, 4218-4237.	1.6	18
116	Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes, Obesity and Metabolism, 2020, 22, 2493-2498.	4.4	26
117	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006758.	3.9	8
118	Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiology, 2020, 5, 871.	6.1	24
119	Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. American Journal of Medicine, 2020, 133, e716-e721.	1.5	12
120	Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Pregnancy Hypertension, 2020, 21, 184-190.	1.4	4
121	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. Circulation, 2020, 142, 230-243.	1.6	59
122	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. American Heart Journal, 2020, 226, 13-23.	2.7	7
123	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation, 2020, 141, 1360-1370.	1.6	9
124	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial: Insights from ASCEND-HF. European Journal of Heart Failure, 2020, 22, 1022-1031.	7.1	27
125	Regional adiposity and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 1540-1550.	7.1	69
126	Pre-discharge initiation of Ivabradine in the Management of Heart Failure: Results of the PRIME-HF Trial. American Heart Journal, 2020, 223, 98-105.	2.7	12



#	ARTICLE	IF	CITATIONS
127	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	7.1	33
128	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 85-101.	1.5	2
129	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	2.4	5
130	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1451-1461.	7.1	12
131	Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006134.	3.9	29
132	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. <i>American Heart Journal</i> , 2020, 225, 3-9.	2.7	12
133	Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?. <i>American Heart Journal</i> , 2020, 226, 69-74.	2.7	7
134	Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. <i>American Journal of Cardiology</i> , 2020, 127, 64-72.	1.6	8
135	Reassessing Recipient Mortality Under the New Heart Allocation System. <i>JACC: Heart Failure</i> , 2020, 8, 548-556.	4.1	83
136	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , 2020, 9, e015752.	3.7	11
137	Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. <i>Clinical Cardiology</i> , 2019, 42, 256-263.	1.8	9
138	Population-Attributable Risk for Cardiovascular Disease Associated With Hypertension in Black Adults. <i>JAMA Cardiology</i> , 2019, 4, 1194.	6.1	48
139	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	4.1	30
140	Increased eGFR Variability is Observed in Patients with HFrEF Compared to no HF or HFpEF in the Setting of Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, S92.	1.7	0
141	Trends in Place of Death for Individuals With Cardiovascular Disease in the United States. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1943-1946.	2.8	17
142	Depressive symptoms, physical activity, and clinical events: The ADAPT prospective pilot study. <i>Clinical Transplantation</i> , 2019, 33, e13710.	1.6	14
143	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088.	1.6	49
144	Patterns of Change in Quality of Life with a Palliative Care Intervention for Patients with Advanced Heart Failure: Insights from PAL-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, S154-S155.	1.7	1

#	ARTICLE	IF	CITATIONS
145	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCel trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138.	6.8	48
146	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	7.1	2
147	Subcutaneous Furosemide in the Treatment of Patients with Decompensated Heart Failure: Data from the Sub-Q Pilot Studies. <i>Journal of Cardiac Failure</i> , 2019, 25, S75.	1.7	3
148	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	2.7	4
149	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
150	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
151	African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial. <i>Journal of Cardiac Failure</i> , 2019, 25, 693-694.	1.7	9
152	Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. <i>JACC: Heart Failure</i> , 2019, 7, 371-382.	4.1	36
153	Characteristics and Trends Among Patients With Cardiovascular Disease Referred to Palliative Care. <i>JAMA Network Open</i> , 2019, 2, e192375.	5.9	43
154	10-Year Risk Equations for Incident Heart Failure in the General Population. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2388-2397.	2.8	107
155	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCel TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	2.8	1
156	Clinical profiles in acute heart failure: an urgent need for a new approach. <i>ESC Heart Failure</i> , 2019, 6, 464-474.	3.1	42
157	Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1081.	7.4	238
158	Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study. <i>American Heart Journal</i> , 2019, 212, 72-79.	2.7	15
159	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	2.2	195
160	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. <i>Journal of Palliative Medicine</i> , 2019, 22, 437-441.	1.1	11
161	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	1.7	19
162	Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does It Really Mark the Spot?. <i>Current Heart Failure Reports</i> , 2019, 16, 250-256.	3.3	1

#	ARTICLE	IF	CITATIONS
163	Patients Accept Mortality Risk for Improvements in Physical Functioning in Secondary Mitral Regurgitation. <i>Journal of Cardiac Failure</i> , 2019, 25, S149.	1.7	1
164	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225.	1.5	15
165	Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 1056-1065.	4.1	21
166	Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008051.	3.9	14
167	Frailty Among Older Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1079-1088.	4.1	61
168	Clinical Effectiveness of Sacubitril/valsartan among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2019, 25, 937.	1.7	3
169	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	3.9	25
170	Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. <i>European Journal of Heart Failure</i> , 2019, 21, 63-70.	7.1	42
171	Potassium Abnormalities Across the Spectrum of Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 77-79.	4.1	2
172	Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans. <i>JAMA Cardiology</i> , 2019, 4, 51.	6.1	38
173	Hospice Care for Heart Failure: Challenges Faced by Hospice Staff in a Predominantly Rural Setting. <i>Journal of Palliative Medicine</i> , 2019, 22, 7-8.	1.1	8
174	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	8.6	23
175	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	2.6	20
176	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction—Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. <i>American Heart Journal</i> , 2018, 199, 97-104.	2.7	9
177	The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions. <i>European Journal of Heart Failure</i> , 2018, 20, 963-972.	7.1	35
178	Interaction of Body Mass Index on the Association Between N-Terminal Pro-B-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study) Tj ETQq0 0.0 rgBT /Overlock 10 Association, 2018, 7, .	3.7	12
179	Cigarette Smoking and Incident Heart Failure. <i>Circulation</i> , 2018, 137, 2572-2582.	1.6	96
180	Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1166-1166.	7.1	2

#	ARTICLE	IF	CITATIONS
181	Traveling the Interstices of Data Sharing. <i>JACC: Heart Failure</i> , 2018, 6, 533-535.	4.1	1
182	Outpatient Worsening Heart Failure as a Target for Therapy. <i>JAMA Cardiology</i> , 2018, 3, 252.	6.1	90
183	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2018, 200, 134-140.	2.7	8
184	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	7.1	29
185	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	11.4	451
186	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	2.7	10
187	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	4.1	4
188	Paving a Better Path for Patients Dying of Heart Disease. <i>Circulation</i> , 2018, 137, 1216-1217.	1.6	5
189	Intentional and unintentional medication non-adherence in African Americans: Insights from the Jackson Heart Study. <i>American Heart Journal</i> , 2018, 200, 51-59.	2.7	15
190	Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. <i>Journal of Clinical Apheresis</i> , 2018, 33, 469-479.	1.3	2
191	Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 118-127.	1.8	24
192	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	7.1	42
193	Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 1011-1019.	4.1	22
194	Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , 2018, 11, e005629.	3.9	24
195	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2576-2578.	1.6	13
196	Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005254.	3.9	129
197	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2231.	7.4	72
198	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	3.7	19

#	ARTICLE	IF	CITATIONS
199	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	2.2	13
200	Causes of Death Among Patients with and without Diabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S69.	1.7	0
201	Top Ten Tips for Palliative Care Clinicians Caring for Heart Failure Patients. <i>Journal of Palliative Medicine</i> , 2018, 21, 1646-1650.	1.1	6
202	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053.	1.6	24
203	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	1.8	22
204	Hyperkalemia in Heart Failure: Probably Not OâœKâœ. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	10
205	Multiâœethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HFâœACTION trial and the ASIANâœHF registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1281-1289.	7.1	23
206	Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 41-44.	2.8	1
207	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 122, 999-1007.	1.6	5
208	Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. <i>American Heart Journal</i> , 2018, 204, 163-173.	2.7	42
209	Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. <i>American Heart Journal</i> , 2018, 205, 133-141.	2.7	13
210	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30	1.6	6
211	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. <i>American Heart Journal</i> , 2018, 204, 202-204.	2.7	14
212	Vaccination Trends in Patients With HeartâœFailure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	4.1	30
213	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	1.6	16
214	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	1.8	10
215	Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.6	9
216	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	2.8	72

#	ARTICLE	IF	CITATIONS
217	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes, 2018, 67, .	0.6	42
218	EXSCELâ€™ Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. Diabetes, 2018, 67, 1319-P.	0.6	0
219	Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group. Diabetes, 2018, 67, 130-LB.	0.6	0
220	Can Vaccinations Improve Heart Failure Outcomes?. JACC: Heart Failure, 2017, 5, 194-203.	4.1	47
221	Return on Investment in Implantable Devices. JACC: Heart Failure, 2017, 5, 213-215.	4.1	1
222	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. European Journal of Heart Failure, 2017, 19, 974-986.	7.1	29
223	Achieving a Maximally Tolerated Î²-Blocker Dose in Heart Failure Patients. Journal of the American College of Cardiology, 2017, 69, 2542-2550.	2.8	41
224	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	15
225	Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease. Circulation: Heart Failure, 2017, 10, .	3.9	35
226	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. JACC: Heart Failure, 2017, 5, 507-517.	4.1	78
227	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3029-3039.	2.8	69
228	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fractionâ€™ Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. American Heart Journal, 2017, 186, 130-138.	2.7	27
229	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. Journal of the American College of Cardiology, 2017, 69, 766.	2.8	2
230	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. Journal of the American College of Cardiology, 2017, 69, 767.	2.8	0
231	EFFECTS OF AGE AND COMORBIDITIES ON OUTCOMES IN PATIENTS WITH HEART FAILURE FROM HF-ACTION. Journal of the American College of Cardiology, 2017, 69, 908.	2.8	1
232	Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. Current Heart Failure Reports, 2017, 14, 30-39.	3.3	6
233	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1683-1691.	2.8	45
234	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 305-309.	4.1	101

#	ARTICLE	IF	CITATIONS
235	Site Principal Investigators in Multicenter Clinical Trials. <i>Circulation</i> , 2017, 135, 1185-1187.	1.6	10
236	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	2.7	49
237	Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals. <i>JAMA Cardiology</i> , 2017, 2, 644.	6.1	30
238	Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. <i>American Heart Journal</i> , 2017, 185, 130-139.	2.7	71
239	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	4.1	84
240	Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. <i>American Heart Journal</i> , 2017, 183, 54-61.	2.7	33
241	Loop Diuretic Change in Patients with Chronic Heart Failure: Insights From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2017, 23, S65-S66.	1.7	0
242	The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, S109.	1.7	0
243	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	27.0	1,455
244	Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. <i>American Heart Journal</i> , 2017, 192, e3.	2.7	1
245	Palliative Care in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 331-341.	2.8	425
246	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	6.1	199
247	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017, 191, 75-81.	2.7	31
248	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	1.8	13
249	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.6	49
250	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	6.1	23
251	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	7.1	22
252	Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1399-1406.	2.8	171

#	ARTICLE	IF	CITATIONS
253	Can 2 Pills a Day Keep Readmission Away?. Journal of the American College of Cardiology, 2016, 68, 249-251.	2.8	3
254	Statins and Exercise Training Response in Heart Failure Patients. JACC: Heart Failure, 2016, 4, 617-624.	4.1	9
255	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 2016, 18, 306-313.	7.1	36
256	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. European Journal of Heart Failure, 2016, 18, 684-692.	7.1	14
257	The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure. Journal of Cardiac Failure, 2016, 22, 939.	1.7	0
258	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. Journal of the American Heart Association, 2016, 5, .	3.7	5
259	Assessment of Administrative Data to Identify Acute Myocardial Infarction in Electronic Health Records. Journal of the American College of Cardiology, 2016, 67, 2441-2442.	2.8	8
260	Exercise Training in Patients with Chronic Heart Failure and Atrial Fibrillation: Results from the HF-ACTION Trial. Journal of Cardiac Failure, 2016, 22, S71.	1.7	2
261	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. Journal of Cardiac Failure, 2016, 22, S27.	1.7	0
262	Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). Journal of the American College of Cardiology, 2016, 68, 1815-1817.	2.8	30
263	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. Circulation: Heart Failure, 2016, 9, .	3.9	15
264	Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. American Journal of Cardiology, 2016, 118, 733-738.	1.6	23
265	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	1.7	11
266	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circulation: Heart Failure, 2016, 9, .	3.9	20
267	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2016, 178, 198-205.	2.7	14
268	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	7
269	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). American Journal of Cardiology, 2016, 118, 1211-1216.	1.6	11
270	A Gordian knot: disentangling comorbidities in heart failure. European Journal of Heart Failure, 2016, 18, 759-761.	7.1	1



#	ARTICLE	IF	CITATIONS
271	Cardiorenal Interactions. Heart Failure Clinics, 2016, 12, 335-347.	2.1	11
272	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	4.1	48
273	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Ove	1.6	26
274	The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. Journal of Cardiac Failure, 2016, 22, 589-597.	1.7	19
275	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. American Journal of Cardiology, 2016, 117, 946-951.	1.6	23
276	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	2.7	82
277	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. American Journal of Cardiology, 2016, 117, 1144-1150.	1.6	23
278	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	1.6	47
279	Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. Journal of Cardiac Failure, 2016, 22, 485-491.	1.7	40
280	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. Journal of Cardiac Failure, 2016, 22, 884-890.	1.7	35
281	Comorbidities in Heart Failure: Are There Gender Differences?. Current Heart Failure Reports, 2016, 13, 1-12.	3.3	37
282	Good Clinical Practice Guidance and Pragmatic Clinical Trials. Circulation, 2016, 133, 872-880.	1.6	79
283	Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. Journal of Cardiac Failure, 2016, 22, 545-547.	1.7	1
284	Discharge heart rate and $\beta$ -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. American Heart Journal, 2016, 173, 172-178.	2.7	28
285	Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?. Journal of Cardiac Failure, 2016, 22, 182-189.	1.7	118
286	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. Journal of Cardiac Failure, 2016, 22, 853-858.	1.7	7
287	Air Pollution in Patients With Heart Failure. JACC: Heart Failure, 2016, 4, 65-67.	4.1	9
288	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. Journal of Heart and Lung Transplantation, 2016, 35, 362-369.	0.6	36

#	ARTICLE	IF	CITATIONS
289	Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 365-373.	2.1	21
290	Pathophysiology and clinical evaluation of acute heart failure. <i>Nature Reviews Cardiology</i> , 2016, 13, 28-35.	13.7	120
291	Volume Assessment and Management: Medical and Device Therapies. , 2016, , 125-163.		0
292	Prognostic Significance of Depression in Blacks With Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 497-503.	3.9	14
293	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	2.7	8
294	Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs. <i>Journal of Cardiac Failure</i> , 2015, 21, S121-S122.	1.7	2
295	Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure?. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 401-403.	1.5	1
296	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	7.1	24
297	Torsemide Versus Furosemide in Heart Failure Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 438-443.	1.9	28
298	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	2.7	38
299	A Call for Collaboration. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2348-2351.	2.8	7
300	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	3.9	235
301	Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America. <i>Heart Failure Clinics</i> , 2015, 11, 581-589.	2.1	5
302	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2015, 8, 1044-1051.	3.9	52
303	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. <i>Circulation: Heart Failure</i> , 2015, 8, 243-251.	3.9	20
304	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. <i>Future Cardiology</i> , 2015, 11, 585-595.	1.2	23
305	COPD in Heart Failure. <i>Chest</i> , 2015, 147, 586-588.	0.8	4
306	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	4.1	95

#	ARTICLE	IF	CITATIONS
307	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	4.1	265
308	A reappraisal of loop diuretic choice in heart failure patients. <i>American Heart Journal</i> , 2015, 169, 323-333.	2.7	83
309	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , 2015, 116, 1304-1310.	1.6	5
310	Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 608-609.	1.7	4
311	End-of-life Heart Failure Care in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 615-623.	2.1	11
312	Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. <i>Journal of Cardiac Failure</i> , 2015, 21, 741-750.	1.7	28
313	Longitudinal Strain in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, 368-370.	1.6	13
314	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	1.5	10
315	Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314.	2.7	20
316	Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682.	2.8	116
317	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	1.7	28
318	Tolvaptan in Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 997-1005.	3.9	26
319	Hospitalized Heart Failure in the United States. <i>Heart Failure Clinics</i> , 2015, 11, 591-601.	2.1	3
320	Cardiac Contractility Modulation: The Next Cardiac Resynchronization Therapy or Another Renal Sympathetic Denervation?. <i>Journal of Cardiac Failure</i> , 2015, 21, 24-26.	1.7	2
321	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	1.6	35
322	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. <i>Circulation</i> , 2015, 132, .	1.6	0
323	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	48
324	Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. <i>European Journal of Heart Failure</i> , 2014, 16, 854-860.	7.1	16

#	ARTICLE	IF	CITATIONS
325	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	2.8	424
326	Decongestion in acute heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 471-482.	7.1	113
327	Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 251-258.	2.8	33
328	Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes. <i>Current Heart Failure Reports</i> , 2014, 11, 416-427.	3.3	46
329	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1843-1851.	1.7	14
330	The Palliative Care in Heart Failure Trial: Rationale and design. <i>American Heart Journal</i> , 2014, 168, 645-651.e1.	2.7	45
331	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	3.9	34
332	Torsemide vs. Furosemide in Heart Failure Patients: Insights from Duke University Hospital. <i>Journal of Cardiac Failure</i> , 2014, 20, S95.	1.7	0
333	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	1.6	8
334	Sleep-Disordered Breathing in Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 243-250.	2.1	13
335	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 614-624.	7.1	71
336	Charting a Roadmap for Heart Failure Biomarker Studies. <i>JACC: Heart Failure</i> , 2014, 2, 477-488.	4.1	81
337	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	2.7	34
338	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014, 19, 135-152.	3.9	48
339	Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 527-532.	2.1	4
340	Association of Beta-Blocker Use and Selectivity With Outcomes in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease (from OPTIMIZE-HF). <i>American Journal of Cardiology</i> , 2013, 111, 582-587.	1.6	71
341	Comparable Clinical Benefits with Beta-Blockers in Heart Failure Patients from North America and Europe: Evidence from a Meta-Analysis of Randomized Clinical Trials. <i>Journal of Cardiac Failure</i> , 2013, 19, S28.	1.7	0
342	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.	2.7	30

#	ARTICLE	IF	CITATIONS
343	Noncardiac Comorbidities and Acute Heart Failure Patients. <i>Heart Failure Clinics</i> , 2013, 9, 359-367.	2.1	52
344	Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). <i>American Heart Journal</i> , 2013, 165, 193-199.	2.7	77
345	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.1	39
346	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 61-68.	7.1	21
347	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	1.7	97
348	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise Training (HF-ACTION). <i>American Heart Journal</i> , 2013, 166, 488-495.e1.	2.7	29
349	Response to Global cardiovascular clinical trials and geographic altitude. <i>American Heart Journal</i> , 2013, 165, e15.	2.7	0
350	SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL. <i>Journal of the American College of Cardiology</i> , 2013, 61, E631.	2.8	0
351	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 571-579.	2.8	58
352	Â-blockers for heart failure: which works best?. <i>BMJ</i> , The, 2013, 346, f480-f480.	6.0	1
353	Dysphagia in the Setting of Left Ventricular Assist Device Hemolysis. <i>ASAIO Journal</i> , 2013, 59, 322-323.	1.6	5
354	Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure?. <i>Circulation: Heart Failure</i> , 2013, 6, 869-876.	3.9	5
355	Haemoconcentration, renal function, and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	7.1	119
356	Association between diabetes mellitus and postdischarge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 194-202.	7.1	155
357	The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	7.1	115
358	Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. <i>European Journal of Heart Failure</i> , 2012, 14, 395-403.	7.1	85
359	Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial?. <i>Journal of Cardiac Failure</i> , 2012, 18, 413-422.	1.7	33
360	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 515-523.	1.7	62

#	ARTICLE	IF	CITATIONS
361	Implications of geographical variation on clinical outcomes of cardiovascular trials. American Heart Journal, 2012, 164, 303-312.	2.7	44
362	Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. American Heart Journal, 2012, 164, 884-892.e2.	2.7	24
363	Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2012, 59, 2145-2153.	2.8	142
364	Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 61.	2.7	10
365	Comparison of Clinical Characteristics and Long-Term Outcomes of Patients With Ischemic Cardiomyopathy With Versus Without Angina Pectoris (from the Duke Databank for Cardiovascular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 61.	2.7	10
366	Cardiorenal Syndrome Clinical Trial End Points. Heart Failure Clinics, 2011, 7, 519-528.	2.1	5
367	Epidemiology of Cardiorenal Syndrome. Cardiology Clinics, 2011, 29, 301-314.	2.2	9
368	Association between VE-VCO2 Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database. Journal of Cardiac Failure, 2011, 17, S8-S9.	1.7	0
369	Clinical Characteristics and Outcomes of Patients with Ischemic Cardiomyopathy (ICM) and Angina: Findings from the Duke Cardiovascular Database. Journal of Cardiac Failure, 2011, 17, S81-S82.	1.7	0
370	Clinical Characteristics and Outcomes for Hospitalized Heart Failure (HF) Patients with Chronic Obstructive Pulmonary Disease (COPD): Findings from OPTIMIZE-HF. Journal of Cardiac Failure, 2011, 17, S86-S87.	1.7	0
371	International Differences in Acute Heart Failure (AHF) Patients: Insight from the PROTECT Trial. Journal of Cardiac Failure, 2011, 17, S59-S60.	1.7	0
372	Natriuretic Peptide-Guided Therapy for Heart Failure. Circulation Journal, 2011, 75, 2031-2037.	1.6	13
373	Epidemiology of Cardiorenal Syndrome. Heart Failure Clinics, 2010, 6, 333-346.	2.1	14